Finally, the ability of sIL18 to limit the progression of B16-F10 melanomas established in WT C57BL/6 mice was abolished with the administration of an antibody blocking the ISG15 receptor integrin alpha L (ITGAL, best known as LFA-1α), as well as by the deletion of Isg5 in malignant cells.1 Here, ITGAL is linked to melanoma.